Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • Lung inflammatory injury and tissue repair (Jul 2023)
    • Immune Environment in Glioblastoma (Feb 2023)
    • Korsmeyer Award 25th Anniversary Collection (Jan 2023)
    • Aging (Jul 2022)
    • Next-Generation Sequencing in Medicine (Jun 2022)
    • New Therapeutic Targets in Cardiovascular Diseases (Mar 2022)
    • Immunometabolism (Jan 2022)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Commentaries
    • Research letters
    • Letters to the editor
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • In-Press Preview
  • Commentaries
  • Research letters
  • Letters to the editor
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Share this article
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
  • Article usage
  • Citations to this article

Advertisement

Research Article Free access | 10.1172/JCI118874

A lung-specific neo-antigen elicits specific CD8+ T cell tolerance with preserved CD4+ T cell reactivity. Implications for immune-mediated lung disease.

R I Enelow, M H Stoler, A Srikiatkhachorn, C Kerlakian, S Agersborg, J A Whitsett, and T J Braciale

Beirne B. Carter Center for Immunology Research, University of Virginia School of Medicine, Charlottesville, Virginia 22908, USA.

Find articles by Enelow, R. in: JCI | PubMed | Google Scholar

Beirne B. Carter Center for Immunology Research, University of Virginia School of Medicine, Charlottesville, Virginia 22908, USA.

Find articles by Stoler, M. in: JCI | PubMed | Google Scholar

Beirne B. Carter Center for Immunology Research, University of Virginia School of Medicine, Charlottesville, Virginia 22908, USA.

Find articles by Srikiatkhachorn, A. in: JCI | PubMed | Google Scholar

Beirne B. Carter Center for Immunology Research, University of Virginia School of Medicine, Charlottesville, Virginia 22908, USA.

Find articles by Kerlakian, C. in: JCI | PubMed | Google Scholar

Beirne B. Carter Center for Immunology Research, University of Virginia School of Medicine, Charlottesville, Virginia 22908, USA.

Find articles by Agersborg, S. in: JCI | PubMed | Google Scholar

Beirne B. Carter Center for Immunology Research, University of Virginia School of Medicine, Charlottesville, Virginia 22908, USA.

Find articles by Whitsett, J. in: JCI | PubMed | Google Scholar

Beirne B. Carter Center for Immunology Research, University of Virginia School of Medicine, Charlottesville, Virginia 22908, USA.

Find articles by Braciale, T. in: JCI | PubMed | Google Scholar

Published August 15, 1996 - More info

Published in Volume 98, Issue 4 on August 15, 1996
J Clin Invest. 1996;98(4):914–922. https://doi.org/10.1172/JCI118874.
© 1996 The American Society for Clinical Investigation
Published August 15, 1996 - Version history
View PDF
Abstract

The A/Japan/57 influenza hemagglutinin (HA) was expressed in BALB/c mice under the transcriptional control of the surfactant protein C (SP-C) promoter, resulting in expression of HA in type II alveolar epithelial cells, as well as low level variable expression in other tissues, including the thymus in some of the founder lines. Transgenic animals were able to recover from infection with A/Japan/57 influenza, and they were able to mount antibody responses to A/Japan/57 HA in titers similar to wild type. We therefore tested their CD4+ T lymphocyte responses to HA and found them to be similar to wild type responses. However, CD8+ T cells from A/Japan/57-infected transgenic animals were unable to express cytolytic activity against target cells expressing the A/Japan/57 HA. The CD8+ T cell tolerance was also extremely specific, since transgenics immunized with an influenza strain containing a single amino acid substitution in a dominant HA epitope were able to mount full cytolytic responses to that epitope, but not the wild-type epitope. Adoptive transfer of CD8+ T cell clones into transgenic animals resulted extensive interstitial pneumonitis that was antigen-specific and associated with significant morbidity and mortality. We conclude that a lung-specific transgene may lead to specific CD8+ T cell tolerance, with CD4+ T cell and B cell reactivity to the antigen, and that CD4+ T cell reactivity may remain intact to an antigen expressed in the thymus, even when CD8+ T cell tolerance exists. This observation may have profound implications concerning immune-mediated lung diseases, particularly those mediated by CD4+ T cells.

Version history
  • Version 1 (August 15, 1996): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Share this article
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2023 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts